The Clinical Observation Of Febuxostat On Hyperuricemia With Dyslipidemia In Male

Objective: This study was to compare the efficacy and safety of febuxostat and allopurinol in the treatment of male patients with hyperuricemia and dyslipidemia,and to evaluate the efficacy and safety of febuxostat in the treatment of male hyperuricemia with dyslipidemia safety.Methods: 90 male patients with hyperuricemia and dyslipidemia were selected from January,2015 to June,2016,while they were admitted to the clinic of Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine.Patients were randomized into a febuxostat 40 mg group(n= 30),a febuxostat 80 mg group(n =30)and an allopurinol group(n = 30).The blood uric acid of patients before and after treatment respectively(UA),total cholesterol(TC),serum glycerin three greases(TG),low density lipoprotein(LDL),high density lipoprotein(HDL),C reactive protein(CRP),endothelin-1(ET-1),renal function(SCr)and liver function(ALT,AST)were detected and compared the evaluation.And observe and record the treatment of patients in the course of adverse reactions and comparative evaluation.Results:1?The effectiveness of febuxostat treatment of hyperuricemia with dyslipidemia:The levels of UA,TG,TC,HDL and LDL in the patients with hyperuricemia and dyslipidemia were not significantly different before and after the experiment(P>0.05).After 12 weeks of treatment,the serum levels of UA were significantly decreased in the low-dose group,high-dose group and allopurinol group,and the difference was statistically significant before treatment(P<0.05).Febuxostat high dose group and low dose group,allopurinol group compared the serum level of UA decreased significantly after treatment,and the difference was statistically significant(P<0.05).The serum levels of TG,TC and LDL in patients of high-dose group were lower than those before treatment(P<0.05),and there were significant differences.The serum HDL level increased after treatment in this group,and the difference was statistically significant(P<0.05).The TG level in the low-dose group was changed after treatment,and the difference was statistically significant(P<0.05).TG level in the high-dose group was lower than that in the low-dose group,and the difference was statistically significant(P<0.05).TC,HDL and LDL in allopurinol group before and after treatment were not statistically significant(P>0.05).Febuxostat in high dose group of patients in the treatment of patients with early incidence of gout is slightly higher than the low dose group and allopurinol group,but the difference was not statistically significant(P>0.05).2?The safety analysis of febuxostat treatment of hyperuricemia with dyslipidemia : The test group before treatment,the security index:SCr,CRP and ET-1do not have significant difference in baseline differences(P>0.05).The comparison between the three groups of CRP and ET-1 levels after the treatment,the difference was not statistically significant(P>0.05).After the treatment of low dose group and high dose group SCr levels compared with allopurinol group level is slightly lower,and the difference was statistically significant(P<0.05).Higher than the low dose group and high dose group of allopurinol group the level of ALT after treatment,and the difference was statistically significant(P<0.05).There was no significant difference in AST levels between the three groups after treatment(P>0.05).In the early treatment,febuxostat high dose group has slightly higher than the low dose group and allopurinol group on incidence of gout,and the difference was statistically significant(P<0.05),but there was no difference in the incidence of gout in the three groups(P>0.05).In the incidence of adverse reactions,allopurinol group was slightly higher than that of febuxostat in low dose group and high dose group.Conclusion:1?Febuxostat can effectively reduce the level of serum uric acid in the patients with hyperuricemia and dyslipidemia,and improve the abnormal blood lipid level,and does not increase the risk of liver and kidney dysfunction and cardiovascular disease.2?Febuxostat has a better effect than allopurinol on regulation of blood lipids.3?The efficacy of febuxostat in the treatment of male hyperuricemia with dyslipidemia was correlated with the dose.While patients should be treated with a low dose of febuxostat at the beginning to reduce the risk of gout attacks.